Tanya B Dorff, MD
Disclosures:

CURRICULUM VITAE

Tanya Barauskas Dorff, MD

May 12, 2016

 

Personal Information:

Work

Home

USC- Norris Cancer Hospital

1441 Eastlake Avenue, #3445

Los Angeles, CA 90033

6617 Maryland Drive

Los Angeles, Ca 90048

     Phone: 323 865 3905

Citizenship:  United States

     Fax: 323 865 0061

 

    Work Email: dorff@usc.edu

 

 

 

 

 

 

Mission statement

I strive to develop translational clinical trials, with emphasis not only on improving treatment efficacy, but also enhancing quality of life for cancer patients. In addition to conventional clinical trials evaluating rational combinations of targeted therapies in prostate cancer pateints, I seek to lead studies using integrative approaches to cancer care incorporating diet, exercise and herbal therapies. 

 

Education and Professional Appointments

 

Education:

08/92 – 12/95             

B.S., Biology, summa cum laude - University of Houston – Honors College, Houston, TX,

08/96 – 06/00

M.D., AOA, - UCLA School of Medicine              Los Angeles, CA

 

 

 

Post-Graduate Training:

07/00 – 06/03

Internship & residency, internal medicine - Mount Sinai Hospital,               New York, NY

07/03- 07/05

Fellowship, Hematology & Medical Oncology - LAC-USC Medical Center, Los Angeles, CA

07/05 – 7/06

Chief fellow, Medical Oncology - LAC-USC Medical Center, Los Angeles, CA

 

 

 

Honors, Awards:

1992

National Merit Scholar

2000             

ACP/ASIM James R. Klinenberg Certificate of Merit

2000             

AMWA Janet M. Glasgow Memorial Achievement Citation

2000

AOA – Alpha Omega Alpha, Medical Honors Society

2005

Fellowship Teaching Award

2010

Faculty Teaching Award

2010

AUA Western Section Best Poster – 3rd place

2012 & 2014

“Top Doctor” Pasadena Magazine

2014

2016

Faculty Teaching Award – Oncology Fellowship – USC Keck School of Medicine

Mentorship Award – Required Scholarly Project – USC Keck School of Medicine

 

2008 – Present

Assistant Professor of Clinical Medicine

USC, Keck School of Medicine

2008 – Present

Attending Staff

USC Norris Cancer Center

2008 – Present

Facutly

USC + Los Angeles County Medical Center, Los Angeles, CA

2006 – 2008

Faculty - Voluntary

USC + Los Angeles County Medical Center, Los Angeles, CA

2006 – 2008             

Staff Physician

The Angeles Clinic and Research Institute, Los Angeles, CA

2006 – 2008

Attending Staff

St. John’s Hospital, Los Angeles, CA

2006 – 2008

Courtesy Staff

Century City Hospital, Century City, CA

2006 – 2008

Provisional Staff

UCLA, Santa Monica, CA

Academic Appointments:

 

Teaching

 

Didactic Teaching: University of Southern California

Year-Year

Course Name

Hrs

Role

09-2008

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

11-2008

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

12-2008

Oncology Fellowship Didactic Lectures - Prostate Cancer

1 hr

Lecturer 

09-2009

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

10-2009

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

03-2010

Oncology Fellowship Lecturers – ASCO Updates

1 hr

Lecturer

01-2011

Oncology Fellowship Didactic Lectures – Prostate Cancer

1 hr

Lecturer

03-2011

Oncology Fellowship Didactic Lectures – Prostate Cancer ASCO Updates

1 hr

Lecturer

09-2011

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

01-2012

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

07-2012

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

08-2013

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

01-2014

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

02-2014

Oncology Fellowship Didactic Lectures – GU ASCO Updates

1 hr

Lecturer

03-2014

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

04-2014

Dept of Medicine – Resident Core Curriculum Lecture – GI Malignancies

1hr

Lecturer

05-2004

LAC+Usc Medical – Morning Report – Oncology

1 hr

Lecturer

10-2014

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

04-2015

Oncology Fellowship Didactic Lectures – Penile Cancer

1 hr

Lecturer

08-2015

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

09-2015

Oncology Fellowship Didactic Lectures – Bladder Cancer

1 hr

Lecturer

09-2015

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

10-2015

LAC+USc Medical – Morning Report – Oncology

1 hr

Lecturer

09-2009

Norris Cancer Center - Oncology Fellowship Journal Club Lectures - GU

1.5 hr

Lecturer

12-2009

Norris Cancer Center - Oncology Fellowship Journal Club Lectures - GU

1.5 hr

Lecturer

01-2012

Norris Cancer Center - Oncology Fellowship Journal Club Lectures – Bladder Cancer

1.5 hr

Lecturer

11-2012

Norris Cancer Center - Oncology Fellowship Journal Club Lectures – Enzalutamide in CRPC

1.5 hr

Lecturer

07-2013

Norris Cancer Center - Oncology Fellowship Journal Club Lectures – GU

1.5 hr

Lecturer

10-2014

Norris Cancer Center - Oncology Fellowship Journal Club Lectures – GU

1.5 hr

Lecturer

 

 

Undergraduate, Graduate and Medical Student (or Other) Mentorship:

Trainee Name

If past trainee, current position and location

Shelley Jellineo

MRI in staging prostate cancer

Manali Shah

Fasting and chemotherapy toxicity

 

 

Postgraduate Mentorship:

 

Year-Year

Trainee Name

Trainee Type

Dissertation/Thesis/Project Title

2015

Kelly Yap

Fellow

Radium223 timing with Bone Supportive medication (retrospective chart review, in progress)

2014

Gino In

Fellow

Published review article on testis cancer

2014

Eddie Thara

Fellow

Published review article on immune therapy for prostate cancer

2013

Mehmet Hepgur

Fellow

poster at GU ASCO 2013 on SipT and CTC changes resulted in “Merit Award”

2013

Amol Rao

Fellow

Worked on TRC105 consortium protocol, bladder cancer perioperative chemotherapy retrospective case series

2012

Elie Fahed

Fellow

Wrote a review article small cell bladder cancer (published)

 

Tanmai Sexena

Resident

SipT survival parameters data analysis, manuscript drafting

 

Cy wilkins

Resident

Case report of CR to Sip-T             

 

Lucy Brining

Resident

series of immune and inflammatory parameters in men treated with SipT

 

Alev Brown

Resident

Published penile cancer EGFR targeted therapy case report.

 

Ravin Rupani

Resident

retrospective chart review

2013

Eric Beam

Med Student

QOL during PHC trial. ASCO GU 2013 abstract             

2014

Janice Loh

Med Student

Retrospective review of salvage chemotherapy for met TCC.

2015

Adrienne Tran

Med Student

Chart review of GFR and cisplatin toxicity in bladder cancer. ASCO GU 2016 poster

 

 

Service

Department Service:

 

Year-Year

Position, Committee

Organization/Institution

2014 - present

Chair - Quality Assurance Committee

USC  Norris Cancer Center

2010 - present

Chair - GU Cancer Clinical Research Operations

USC  Norris Cancer Center

2008 - present             

Member - Cancer Investigations Committee

USC  Norris Cancer Center

2011- present

Member - Medical Student Required Scholarly Project

USC  Norris Cancer Center

2011- 2014             

Member - Inpatient Safety Committee

LAC-USC

2010 - 2011

Representative - Medical Faculty Assembly

USC Norris Cancer Center

 

 

Professional Society Memberships:

Year- Year

Society

2004 - Present

American Society of Clinical Oncology (ASCO)

Member, Scientific Review Committee GU (Prostate) 2016- present

2009 – Present

SWOG                           

2015 – Present

ACCRU  Co-leader of GU disease group

2015 - Present

Kidney Cancer Association

 

 

Community Service: Community Outreach Lectures

Year-Year

Role or Activity

11-2015

“A new look at the latest approaches in the diagnosis and treatment of prostate cancer” at the Cancer Support Community, Westlake Village, CA.

11-2015

“Radium223: what we do and do not know” at the Prostate Cancer Forum, Fullerton, CA

11-2015

“The Latest Medical and Complementary Interventions in Prostate Cancer Treatment” at the USC Norris Prostate Cancer Support Group.. Los Angeles, CA

01-2015

“The value of chemotherapy in advanced prostate cancer: CHAARTED” at the Prostate Cancer Forum (support group). Fullerton, CA.

9-2014

“Clinical Trials for RCC” at the Orange County Kidney Cancer Support Group. Irvine, CA

5-2014

“Herbs and fasting: integrating alternative medicine into prostate cancer care” at the San Jose US, TOO prostate cancer support group.. San Jose, CA.

4-2014 

“Nutritional supplements and prostate cancer” at the Men’s Health Network support group meeting. Vernon, CA.

1-2014

“Nutrition and Supplements for Prostate Cancer” at USC Institute of Urology, Life after prostate cancer patient information seminar. USC Health Sciences.

1-2013

“The latest approaches for treating prostate cancer” at the Cancer Support Community. Thousand Oaks, CA.

 

 

4-2012

“New Ideas and Unconventional Approaches for Prostate Cancer” at the Prostate Cancer Forum prostate cancer support group.  Fullerton, CA.

11-2011

“Prostate Cancer Treatment” (panel) at Riverside Medical Foundation prostate cancer support group.

6-2008

“Prostate Cancer Update 2008” at the Wellness Community, US TOO support group meeting. 

5-2008

“Surviving and Getting the Most out of Hormone Therapy for Prostate Cancer” USC Prostate Cancer Forum.

11-2007

“Looking to the Future:  New Hope for Prostate Cancer Therapy”  Riverside Medical Foundation, 25th anniversary celebration lecture.  Riverside CA.

10-2007

“Optimizing Hormone Therapy – Beyond Standard Therapy”  Prostate Awareness Foundation, San Francisco CA.

9-2007

“Cancer de la Prostata: Lo que Cada Hombre (y Mujer) debe saber”  Wellness Community, San Fernando Valley CA.

3-2007

”Highlights of the ASCO Prostate Cancer Symposium” - Silicone Valley Prostate Cancer Center and US Too Prostate Cancer Support Groups, San Jose, CA.

Research and Scholarship

 

Editorships and Editorial Boards:

Year-Year

Position

Journal/Board Name

2015 - present

Associate Editor

Therapeutic Advances in Medical Oncology             

2015 - present

Associate Editor

Clinical Genitourinary Cancer

 

Year-Year

Journal

2013-present

Annals of Oncology

2016

Cancer

2013-present

Clinical Genitourinary Cancer

2013-present

Journal of Clinical Oncology

2015-present

Lancet Oncology

Manuscript Review:

2012

Nature Reviews Urology

2015-present

Prostate Cancer Prostatic Diseases

2012-present

Therapeutic Advances in Medical Oncology

2014

Urologic Oncology

2014

World Journal of Urology

 

 

Grant Reviews:

 

 

Major Areas of Research Interest

 

Genitourinary Cancer Research

Supportive care and complementary/alternative medicine

 

 

Grant Support - Completed:

 

Grant No. HHSN26120120051C    Dorff

Dates of Award:  09/28/12-08/31/2015

Agency L-Nutra

Percent Effort 4%

Title: “Chemolieve: Differential Protection of Normal versus Cancer Cells in Patients Receiving Chemotherapy”

Description: The goals of this project are to perform a randomized, phase II clinical trial to test the impact of Chemolieve on Toxicity and efficacy of chemotherapy for breast cancer; to evaluate the compliance with a controlled diet intervention and investigate changes in plasma insulin, glucose, IGF1 and IGF binding protein levels and inflammatory markers in subjects who consume Chemolieve compared to controls

  Role: Principal Investigator (Sub-contract)

Total Direct Costs: $260,409.00

 

Grant No: 5 R01 CA148756  (PI)   Pinski

Dates of Award09/01/2010 – 08/31/2015

Agency: NCI/NIH

Percent Effort: 3%

  Title:               Targeted Therapy to Receptors for LH-RH in Prostate Cancer.

  Description: This project explores a novel agent that targets LH-RH receptors, which are highly expressed on prostate cancer cells but not on normal tissues. Correlative studies will investigate several novel assessment techniques, including a new technique to collect circulating tumor cells that appears to be more practical and less expensive than current methods. 

  Role: Co-Investigator

Total Direct Costs: $1,034,573

 

Grant No. N/A       (PI) Longo

Dates of Award: 01/01/20009 – 12/31/2011

Agency: Blackwell Foundation

Percent Effort: 10%

  Title: Foods and Nutraceuticals for the Differential Protection Against Chemotherapy and Radiotherapy.

Description: This funded laboratory exploration of a fasting-mimic diet and part of a clinical trial testing the role of the diet in reducing chemotherapy toxicity.

  Role: Co-Investigator

Total Direct Costs: $545,209

 

Grant No. N/A     (PI) Dorff

Dates of Award: 01/04/2010 – 12-31-2010

Agency: Medical Women Faculty Association (USC)

Percent Effort: 1%

Title: The USC Experience with Penile Squamous Cell Carcinoma: Influence of Primary Surgical Therapy, Adjuvant Therapy, and Expression of EGFR and ERCC1.     

Description: This funded tissue immunohistochemistry and mRNA evaluation of penile cancer tissue specimens.

  Role: Principal Investigator

Total Direct Costs: $10,000

 

Grant No: .  N/A    (PI) Longo/Quinn

Dates of Award: 11/01/2008 – 10/31/2012

Agency: V Foundation

Percent Effort 1%

  Title:               Short Term Starvation prior to Chemotherapy:  Effect on Adverse Events Related to Chemotherapy and the Unfolded Protein Response.

  Description: This funded our phase I clinical trial of fasting prior to platinum chemotherapy to evaluate safety, changes in oxidative stress and IGF pathway, and part of the ongoing randomized II with clinical endpoint of reducing chemotherapy-related toxicity.

  Role: Co-Investigator

Total Direct Costs: $71,259

 

Grant No. N/A       (PI) Quinn

Dates of Award: 07/01/2009-03/31/2010             

Agency: Whittier Foundation

Percent Effort: 1%

  Title: A Phase II Clinical Trial of Prostate Health Cocktail for PSA recurrence after prostatectomy or radiation therapy

  Description: This funded a clinical trial of a combination herbal supplement in men with biochemically recurrent prostate cancer, with correlative science including CTCs.

  Role: Co-Investigator

Total Direct Costs: $72,318

 

Invited Lectures, Symposia, keynote addresses

Year

Type

Title, Location

February 2016

Grand Rounds

“Fasting and Oxidative Stress Resistance in Cancer Patients”, Winship Grand Rounds at Emory; Atlanta, Georgia

October 2015

Invited Lecture

“Radium223: optimizing its use for the future” and “Moving Sipuleucel-T Forward”, Summit on GU Malignancies, Banff, Canada.

Sept 2015

Invited Lecture CME

“Advanced Prostate Cancer Management” at Society of Utah Medical Oncologists. Salt Lake City, UT.

August 2015

Invited Lecture CME

“Next-generation angiogenesis inhibitors” and “Renal Cell Cancer Agents in Development” at the California Cancer Consortium metting, Pasadena, CA.

June 2015.

Invited Lecture CME

“Radium223: Defining timing, patients, and duration with limited data”. Educational Session at ASCO Annual Meeting

Apr 2015.

Invited Lecture CME

“Fasting and oxidative stress resistance: What have we learned so far?”  USC Norris Cancer Center Grand Rounds. Los Angeles CA.

Sept 2013, 2014

&  2015

Invited Lecture CME

“Prostate Cancer”  at Comprehensive Oncology Board Review Course. Seattle, WA.

August 2014

Invited Lecture CME

“New vascular/ angiogenesis targeted therapies”  at the California Cancer Consortium annual meeting,. Pasadena, CA.

May 2014.

Invited Lecture CME.

“Novel Therapeutics and Combinations for Castration Resistant Prostate Cancer” at ASCO 2014 Annual Meeting (poster discussant). Chicago, IL.

February 2014

Invited Lecture

“Radium223 for metastatic prostate cancer: a clinical perspective” and “Molecular Imaging for Prostate Cancer: emerging modalities and unmet needs” at the Society of Nuclear Medicine and Molecular Imaging Pacific Northwest Chapter Annual meeting. Honolulu,. VOICE credits.

October 2013.

Invited Lecture CME

“Fasting and Fasting-Mimic Diet prior to Chemotherapy to Reduce Side Effects and Enhance Efficacy” workshop at Society of Integrative Oncology. Vancouver,

April 2013.

Invited Lecture CME

“Herbs and Fasting: advancing science-based integration of alternative medicine in the cancer center” at City of Hope Grand Rounds.

Nov 2012.

Invited Lecture CME

“Incorporating peri-operative chemotherapy for muscle-invasive bladder cancer to enhance cure”. at USC Institute of Urology Bladder Cancer Symposium.

October 2012.

Invited Lecture CME

“RCC: biology driving clinical advances” at USC Department of Nephrology Grand Rounds.

August 7, 2012

Invited Lecture

“Current Clinical Trials for RCC” at UC Irvine Urology Grand Rounds.

July 2012.

Invited Lecture CME

“Successful incorporation of Perioperative Chemotherapy for Muscle-invasive bladder cancer to enhance cure” at Todd Cancer Institute (Long Beach, CA) for Urology Cancer Conference,

April 2012.

Invited Lecture

“Balancing risks of ONJ with benefits of bisphosphonate and RANK ligand inhibitor therapy in the high risk solid tumor patient” at the 5th annual Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ) Symposium at USC

January 2012

March 2012

Invited Lecture

CME

“Cancer in the Elderly” at Rancho Los Amigos Grand Rounds, March 2012 and at Northridge Hospital Grand Rounds.

Oct 2011

Invited Lecture CME

“Renal Toxicity of Oncologic Agents” at Nephrology Grand Rounds USC.

Sept 2010

Invited Lecture CME

“Kidney Cancer” at Nephrology Grand Rounds, USC

 

 

October 2010

Invited Lecture CME

“Systemic Therapy for Urothelial Cancer” (), at Society of Utah Medical Oncologists Fall meeting

July 2010.

Invited Lecture CME

“Update for Genitourinary Cancers” Scripps Best of ASCO. Beverly Hills CA

February 2010

Invited Lecture CME

“Chemotherapy for Prostate Cancer” and “Biologic Therapy for Prostate Cancer” at the Community Oncology Conference in Scottsdale, AZ

Oct 2009

Invited Lecture CME

“Immune Therapy for Prostate Cancer” at Current Trends in Genitourinary Oncology meeting, Pasadena CA.

June 2008

Invited Lecture CME

“Systemic Therapy for Advanced Prostate Cancer: New Targets, New Hope” at USC Update in Medicine

 

Invited Lecture CME

“Quarterbacking Treatment Options for Men with Localized Prostate Cancer”.  Community Oncology Conference, Washington D.C., Feb 2008.

Feb. 2006

Invited Lecture CME

“Progress in the Treatment of NSCLC”, USC PCCM Alumni CME

 

 

 

 

Publications (Peer Reviewed):             

 

Wang SJ, Wang MB, Barauskas TM, Calcaterra TC.  Surgical Management of Carotid Body Tumors.

Otolaryngol Head Neck Surg  2000; 123:202-6.

 

Daneshmand S, Dorff TB, Quek MJ, Cai J, Pike MC, Nichols PW, Pinski J.  Ethnic Differences in

Neuroendocrine Cell Expression in Normal Human Prostate Tissue.  Urology 2005; 65:1008-12.

 

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, and

Pinski J.  Prognostic Significance of Neuroendocrine Expression in Lymph Node Positive Prostate

Cancer.  Urology 2006; 67:1247-52.

 

Dorff TB, Shazer RL, Nepomuceno EM, and Tucker SJ.  Successful treatment of metastatic

androgen-independent prostate carcinoma in a trans-sexual.  Clinical Genitourin Cancer 2007

June;5(5):344-6.

 

Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn

DI, Liebman HA.  Subclinical haemostatic activation and current surgeon volume predict bleeding with

open radical retropubic prostatectomy.  BJU Int 2008; 102:1086-91.

 

Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Singer FR, Hoon

D.  A Multimarker Circulating DNA Assay for Assessing Prostate Cancer Patients' Blood.  Clinical

Chemistry 2009; 55:1258.

 

Dorff TB, Wei DT, Miranda G, Skinner DG, Stein JP, Quinn DI.  Adjuvant chemotherapy for locally

advanced urothelial carcinoma:  an overview of the USC experience.  World Journal of Urology 2009;

27:39-44.

 

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei

DD, Twardowski G, Chatta G, McNamara M, Gandara DR.  Oral Fenretinide in Biochemically

Recurrent Prostate Cancer: a California Cancer Consortium Phase II Trial.  Clin Genitourin Cancer

2009; 7:43-50.

 

 

Leibowitz B, Dorff T, Tucker S, Symanowski J, Vogelzang NJ.  Testosterone Replacement in Prostate

Cancer Survivors with Hypogonadal Symptoms.  BJU Int 2009; 105: 1397-1401.

 

Safdie FM¥, Dorff T¥, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD.  Fasting and cancer

treatment in humans: a case series report.  Aging 2009; 1:988-1007.

¥These 2 authors were noted as having contributed equally to the manuscript.

 

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ,

Thompson IM, Hussain MHA.  Clinical and Correlative Results of SWOG S0354: A Phase II Trial of

CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated

Patients with Castration-Resistant Prostate Cancer.  Clin Cancer Res  2010; 16:3028.  PUBMED ID

20484019

 

Mori R, Dorff TB*, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski

JK.  The relationship between proangiogenic gene expression levels in prostate cancer and their

prognostic value for clinical outcomes.  Prostate 2010; 70:1692-1700. PubMed ID 20564320.  (*the

first and second authors were noted as having equal contribution)

 

Desancho MT, Dorff T, Rand JH.  Thrombophilia and the risk of thromboembolic events in women on

oral contraceptives and hormone replacement therapy.  Blood Coagul Fibrinolysis 2010; 21:534-8.

PubMed ID 20581664.

 

Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD.  Fasting and differential

chemotherapy protection in patients. Cell Cycle 2010; 9:4474-6.

 

 

Dorff TB, Flaig TW, Tangen CM, Hussain MA, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA,

Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode MJ.  Adjuvant androgen deprivation

after radical prostatectomy for high-risk prostate cancer: Southwest Oncology Group (SWOG) S9921.

J Clin Oncol 2011; 29:2040-5. PubMed ID 21502546

 

Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S.

Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.  BJU

Internatl  2011; 109:846-54. PM ID 21812902

 

Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J.  Ethnic differences in neuroendocrine

Expression in prostate cancer tissue.  Anticancer Res 2011; 31:3897-901 (PubMedID 22110216)

 

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI.

Prospective evaluation of 18-F NaF and 18-F –FDG PET/CT in detection of occult metastatic disease

in biochemical recurrence of prostate cancer. Clin Nucl Med 2012; 37:637-43.

 

Fairey AS, Daneshmand S, Quinn D, Dorff TB, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda

G, Skinner EC. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs.

methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder:

A retrospective analysis from the University of Southern California. Urol Oncol 2012; E pub (PubMed

ID: 23141776)

 

Jayaratna IS, Mitra AP, Schwartz RL, Dorff TB, Schuckman AK. Clinicopathologic characteristics and

outcomes of penile cancer treated at tertiary care centers in the western united states. Clin GU

Cancer 2013; 12:138-42.

 

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of

oxaliplatin plus pemetrexed in chemotherapy-pretreated metastatic castration-resistant prostate

cancer. Clin GU Cancer 2013; in press

 

Brown A, Ma Y, Danenberg K, Schuckman A, Pinski J, Pagliaro L, Quinn D, Dorff TB. Epidermal

Growth Factor Receptor-Targeted Therapy In Squamous Cell Carcinoma Of The Penis: A Report Of 3

Cases. Urology 2014; 83:159-65

 

Fairey AS, Daneshmand S, Quinn DI, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda

G, Skinner EC. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs.

methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial cancer of the bladder: a

retrospective analysis from the University of Southern California. Urol Oncol 2013; 31:1737-43

 

Dorff TB, Wilkins C, Hepgur M, Quinn DI. Durable complete remission from castration-resistant

prostate cancer with sipuleucel-T after estrogen withdrawal. Clin GU Cancer 2014; 12:e55-8.

 

Mitra AP, Skinner EC, Shuckman AK, Quinn DI, Dorff TB, Daneshmand S. Effect of Gender on

Outcomes following radical cystectomy for urothelial cancer of the bladder: a critical analysis of 1994

patients. Urol Oncol 2014; 32:52-9.

 

Pond GR, DiLorenzoG, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, Dorff TB, Harshman LC,

Milowsky  MI, Lee RJ, Galsky MD,  Federico P, Bolger G, DeShazo M, Mehta A, Goyal J, Sonpavde

G. Prognostic risk stratification derived from individual patient level data for men with advanced penile

squamous cell carcinoma receiving first-line systemic chemotherapy. Urol Oncol 2014; 32:501-8.

 

Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, DaSacco S, Mirisola M, Quinn DI,

DorffTB,Kopchick JJ, Longo VD. “Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoeitic

Stem Cell Based Regeneration and Reverse Immunosuppression”. Cell Stem Cell 2014; 14:810-23.

 

Pond GR, Milowki MI, Kolinsky MP, Eigl BJ, Necchi A, Harshman LC, DiLorenzo G, Dorff TB, Lee RJ,

Sonpavde G. Concurrent chemoradiotherapy for men with locally advanced penile squamous cell

cancer. Clin GU Cancer 2014; 12:440-6. PMID 24787971

 

Dorff TB, Groshen S, Tsao-Wei D, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. A Phase II

Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer.

PCAN 2014; 17:359-65.  PMID 25245366

 

Liu SJ, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai Y-C, Engel J, Hawes D, Schally

AV, Pinski JK. Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in

Patients with Castration- and Taxane-Resistant Prostate Cancer. Clin Cancer Res 2014; 20:6277-83.

PMID 25278449

 

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L,

Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer

Chemother Pharmacol 2014; 74: 1227-34. PM ID: 25374407

 

Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R,

Vinciguerra M, DiBiase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P,

Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Long VD. A periodic diet

that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and

healthspan. Cell Metab 2015; 22:86-99.

Gross ME, Dorff TB, Quinn DI, Agus DB, Luttgen M, Bethel K, Kolatkar A, Kuhn P. Rapid Changes in circulating tumor cells following anti-angiogenic therapy. Conver Sci Phys Oncol 2015; 1:1-7.

Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S. Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prost Cancer Prost Dis 2015; epub

Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB. Patient

experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Prost Cancer Prost Dis 2015; in press.

 

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng C-W, Brandhorst S, Cohen P, Wei M,

Longo V, and Quinn DI. Safety and feasibility of fasting in combination with platinum based chemotherapy. BMC

Cancer 2016; 16:360-9.

 

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M,

Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, Ifosfamide, and cisplatin

efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. J Clin Oncol 2016;

10.1200/JCO.2016.66.7899

 

 

 

 

 

 

 

PUBLICATIONS (Reviews and Commentaries):

 

Dorff TB, Garcia AA.  Neoadjuvant Chemotherapy for Advanced Ovarian Cancer:  A Good Option for Select Patients.  Women’s Oncology Review 2004; 4:73-78.

 

Dorff TB, Garcia AA, Spicer D.  HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomized comparison:  trial stopped – commentary.  Women's Oncology Review 2004; 4:245-46.

 

Dorff T, Garcia AA. Intraperitoneal chemotherapy for the treatment of ovarian cancer. Women’s Oncology Review 2005; 5: 203-11

 

Pinski J, Dorff TB.  Prostate Cancer Metastases to Bone:  Pathophysiology, Pain Management, and the Promise of Targeted Therapy.  Eur J Cancer 2005; 41:932-40.

 

Dorff TB, and Tucker SJ.  Quality of Life during and after chemotherapy for advanced prostate cancer.  Am J Hematol Oncol 2006;6(2):2-4.

 

Dorff TB, Quek ML, Daneshmand S, Pinski J.  Evolving treatment paradigms for locally advanced and metastatic prostate cancer.  Expert Rev Anticancer Ther 2006; 6:1339-51.

 

Dorff TB, Goldkorn A, Cheung EM, Gu HH, Subioc-Averia M, Quinn DI. Update on the Clinical Biology and Therapy of Advanced Renal Cancer. J Clin Cancer Res 2007; 1: 116-129.

 

Cheung EM, Wadhera P, Dorff TB, Pinski J.  Diet and Prostate Cancer Risk Reduction.  Expert Review Anticancer Ther 2008; 8:43-50.

 

Dorff TB, Quinn DI.  Perioperative chemotherapy for urothelial cancer: how have we made a “sow’s ear” out of a chemotherapy-sensitive tumor?  Cancer 2009 115:5139-42.

 

Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MHA.  Cooperative Group Trials:  Southwest Oncology Group (SWOG) Innovations in Advanced Prostate Cancer. Therapeutic Advances in Medical Oncology 2009; 1:69-77.

 

Dorff TB, Quinn DI.  Cabazitaxel in Prostate Cancer: Stretching a String.  Lancet 2010; 376:1119-20.

 

Dorff TB and Vogelzang NJ.  Use of Testosterone Replacement Therapy in Patients with Prostate Cancer.  Curr Urol Rep 2011; 12:223-8. PUBMED ID 21365235 

 

Dorff TB and Pinski J.  Advanced prostate cancer: new agents, new questions.  Commentary on “Evolving therapeutic paradigms in advanced prostate cancer” in Oncology 2011; 25:509-11.  PUBMED ID 21717905

 

Thara E, Dorff TB, Pinski JK, Quinn DI.  Vaccine therapy with Sipuleucel-T (Provenge) for prostate cancer.  Maturitas 2011; 69:296-303.  PUBMED ID 21621934.

 

Dorff TB, Gross ME.  The epothilones: new therapeutic agents for castration-resistant prostate cancer.  The Oncologist 2011; 16:1349-58.

 

Zhang SY, Thara E, Quinn D, Dorff T.  Blood cells and their use in active immunotherapy of prostate cancer.  Hum Vaccin Immunother 2012; 8:. PubMed ID 22370509.

 

Dorff TB, Crawford ED.  Management and Challenges of Corticosteroid Therapy in Men with Metastatic Castrate-Resistant Prostate Cancer. Ann Oncol 2012; 24:31-8. PMID 22831986

 

Fahed E, Hansel DE, Raghavan D, Quinn DI, Dorff TB.  Small cell bladder cancer: biology and management. Sem Oncol 2012; 39:615-8.

 

Dorff TB and Quinn DI.  Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: ‘plus or minus’ may be a minus.  Ann Oncol 2013; 24:270-2. PMID 23341479

 

Dorff TB and Glode LM. Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Curr Opin Urol 2013; epub. PMID 23619581.

 

Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, DiLorenzo G.  Penile cancer: current therapy and future directions. Ann Oncol 2013; 1179-89. PMID 23293117.

 

Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell cancer. Biologics: Targets and Therapy 2013; 7:139-48.

 

Dorff TB and Wong MK.  Weighing the Evidence for Immune Therapy and Targeted Therapy in Renal Cancer and Melanoma. (Commentary) Oncology 2013; 27:691-2.

 

Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, DiLorenzo G. Penile Cancer: current therapy and future directions. Ann Oncol 2013; 24(5):1179-1189.

 

Dorff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharm 2014; 7:67-73.

 

Agarwal N, Dorff T, Goldkorn A. New prostate cancer drugs: extending and improving life. Lancet Oncol 2014; 15:1052-4.

 

Dorff TB, Hu JS, Quinn DI. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston) 2014; 28:498-500.

Vashistha V, Quinn DI, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer 2014; 14:966. PMID 25515347

Dorff TB and Gross ME. Radium223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? ASCO Annual Meeting 2015 Educational Book.

Dorff TB and Pal SK. Hitting prostate cancer where it hurts: maximizing control of osseous metastases. Oncology 2015; 29:424.

In G and Dorff TB. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urologic Clinics of North America. 2015; 42:347-58.

Dorff TB, Hu JS, Quinn DI.  Relapsed and refractory germ cell tumors: finessing the rough end of a beautiful story. Urologic Oncology – Seminars. 2015; 33:341-2.

 

 

BOOK CHAPTERS

 

Dorff T and Quinn D.  Systemic treatment: targeted therapies.  In: Renal Cancer, Oxford Oncology Library, 2010. Edited by Tim Eisen.

 

Ali SL, Dorff TB, Pagnini PG, Quinn DI. Urethral cancer. In: Textbook of Uncommon Cancer.  Wiley, John & Sons, 2012. Edited by Raghavan D.,

 

Dorff TB and Pinski JK.  Chapter 49: The Hormonal Management of Metastatic Prostate Cancer.  In: Urological Oncology, 2nd edition. Springer, 2014. Edited by Nargund V.

 

Dorff TB and Mack P. Chapter 14: The Role of mTOR inhibitors and PI3K Pathway Blockade in Kidney Cancer. In: Kidney Cancer: Principles and Practice Springer Press, 2015 (in press). Edited by Lara P Jr.

 

 

 

Abstracts and Presentations:

 

 

De Sancho MT, Dorff TB, and Rand JH.  Thrombophilic Disorders and the Risk of Thromboembolic Events in Women on Oral Contraceptives and Hormone Replacement Therapy.  Blood (ASH Annual Meeting) 2004, 104(11): Abstract 4021

 

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. “Prognostic significance of neuroendocrine expression in lymph node positive prostate cancer”, ASCO Poster Presentation, May 2005, Orlando

 

Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Lieskovsky S, Skinner DG, Raghavan D, Liebman HA, Quinn DI.  Hemostatic activation, fibrinolysis, and angiogenesis prior to radical prostatectomy:  Prediction of bleeding and prognosis. ASCO Prostate Cancer Symposium, March 2007, Poster Presentation, Orlando

 

Dorff TB, Rupani R, Wei DT, Groshen S, Pinski J, Raghavan D, Quinn D, Aparicio A.  “POMB-ACE Therapy for Patients with International Germ Cell Cancer Collaborative Group (IGCCCG) Poor Risk Germ Cell Tumors (GCT):  the USC Experience”, ASCO, June 2006, Poster Presentation.

 

TM Beer, SF Slovin, CS Higano, S Tejwani, Dorff TB, E Stankovich, I Lowy.  Phase I Trial of Ipilimumab Alone and in Combination with Radiotherapy (XRT) in patients with metastatic Castration-Resistant Prostate Cancer (CRPC).  ASCO June 2007, abstr 5004.

 

Dorff TB, Groshen S, Wei D, Goldkorn A, Korn C, Quinn D, Pinski J.  “Interim Results of a Phase II Trial of Oxaliplatin and Pemetrexed as 2nd/3rd line therapy in Hormone Refractory Prostate Cancer”  ASCO May 2008, abstr 5139 (Poster)

 

Dorff TB, Moyneur E, Barghour V, Quinn DI.  Influence of Age on Comorbidities and Treatment in Patients with Renal Cell Carcinoma:  A Retrospective Claims Database Analysis.  ISPOR May 2009, abstr pcn211 (Poster).

 

Pinski J, Goldman B, Dorff TB, Mack P, Lara P Jr, Van Veldhuizen P, Quinn D, Hussain MHA, Thompson IM.  SWOG S0354:  A Phase II Trial of CNTO328, A Monoclonal Antibody Against Interleukin-6 (IL6) in Chemotherapy Pre-treated Patients with Metastatic CRPC.  ASCO May 2009, abstr 5143 (Poster)

 

Dorff TB, Diekman S, Xiong S, Hawes D, Pinski J.  Ethnic Differences in Neuroendocrine Expression in Prostate Cancer Tissue.  ASCO Genitourinary Cancer Symposium 2010, abstr 197 (poster)

 

Dorff TB, Liu S, Mori R, Xiong S, Ye W, Groshen S, Shimada H, Danenberg KD, Danenberg P, and Pinski JK.  The relationship between androgen receptor and pro-angiogenic gene expression levels in prostate cancer and their prognostic value.  ASCO Genitourinary Cancer Symposium 2010, abstr 17. (Oral abstract presentation)

 

Dorff TB, Cai J, Miranda G, Skinner EC, Schuckman A, Groshen S, Quinn DI.  Impact of dose density of adjuvant chemotherapy for locally advanced urothelial carcinoma.  ASCO 2010 Annual Meeting. Poster presentation (abstr 4567)

 

Dorff TB, Schwartz R, Cai J, Ma Y, Bulbul A, Skinner E, Quinn D, Danenberg K, Schuckman A.  Epidermal Growth Factor Receptor (EGFR), thymidylate synthase (TS) and ERCC1 expression in penile squamous cancer (PSC).  ASCO 2011 Genitourinary Cancer Symposium. Poster presentation (abstr 219).

 

Piatek CI, Desai BB, Tsao-Wei D, Tang R, Acosta F, Pinski JK, Dorff TB, Goldkorn A, Jadvar H, Quinn DI.   RECIST 1.0 versus 1.1: implications for trial interpretation and design in advanced prostate cancer.  ASCO 2011 Annual Meeting, poster presentation (abstr 2563).

 

Liu S, Dorff TB, Wang Q, Xiong S, Thara E, Keng M, Ingles SA, Pinsk JK.  LH receptor polymorphisms and response to androgen deprivation therapy in prostate cancer.  ASCO 2011 Annual Meeting, poster presentation (abstract 4597r)

 

Fairey AS, Daneshmand S, Dorff T, Dorin RP, Lieskovsky G, Quinn D, Schuckman A, Cai J, Miranda G, Skinner EC. Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California. ASCO 2012 Genitourinary Cancers Symposium, poster presentation. (abstr 

 

 

Jayaratna IS, Schwartz RL, Mitra AP, Cai J, Ma Y, Quinn DI, Dorff TB. The University of Southern California penile cancer experience: clinicopathologic characteristics of patients from 1991-2011. ASCO 2012 GU Cancer Symposium, poster presentation (abstr 342).

 

 

 

Liu SV, Schally AV, Dorff TB, Tsao-Wei D, Groshen SG, Xiong S, Hawes D, Quinn DI, Tai YC, Block NL, Engel J, Pinski JK. A phase I trial of AEZS-108 (AN152) in castration- and taxane-resistant prostate cancer. ASCO 2012 GU Cancer Symposium, poster presentation (abstract 60).

 

Fairey AS, Daneshmand S, Dorff TB, Dorin RP, Lieskovsky G, Quinn DI, Schuckman A, Cai J, Miranda G, Skinner E.  Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California. ASCO 2012 GU Cancer Symposium, poster presentation (abstract 301). 

 

 

Schwartz RL, Jayaratna IS, Mitra AP, DaSilva D, Kast WM, Chen M, Ma Y, Quinn DI, Dorff TB, Schuckman A. HPV status in relationship to clinicopathologic variables in patients with penile cancer at LAC-USC Medical Center. ASCO 2012 GU Cancer Symposium, abstr 329 (poster).

 

Dorff TB, Hawes D, Tsao-Wei D, Quinn D, Goldkorn A, Lieskovsky G, Vogelzang N, Groshen S, and Pinski J.  A combination herbal supplement for biochemically recurrent prostate cancer.  ASCO 2012 GU Cancer Symposium, abstr 24 (Poster).

 

Lee GL, Ji L, Gitlitz BJ, Dorff TB, Iqbal S, El-Khoueiry AB, Roman L, Edwards S, Menendez X, Cheng P, Quinn DI, Cole S, Garcia A.  Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. ASCO 2012 Annual Meeting, abstr e13084.

 

Harshman LC, Bepler G, Quinn DI,  McKenney J, Hawes D, Simon N, Srinivas S, Dorff TB.  Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy. ASCO 2012  Annual Meeting, abstr e15005.

 

Plimack ER, Nemec C, Elson P, Suarez C, Dorff TB, Larkin JMG, McAleer C, Nunez I, Fisher RA, Rini BI. An observational study of renal cell carcinoma patients prior to initiation of systemic therapy. ASCO 2012 Annual Meeting, abstr TPS4679.

 

Quinn DI, Hamid O, Tsao-Wei D, Hu J, Pinski J, Schuckman A, Daneshmand S, Groshen S, Raghavan D, Corn K, Massopust K, Ketchens C, Aparicio A, Dorff TB. Gemcitabine, Oxaliplatin, And Paclitaxel (GOT) on a 2-weekly Schedule In Patients (pts) With Refractory Germ Cell Carcinoma: A phase II study conducted at the University of Southern California. ESMO 2012 Annual Meeting, proffered paper oral presentation, abstr 7900.

 

Gross ME, Agus D.B., Dorff TB, Pinski JK, Quinn DI, Dago AE, Stepansky A, Carlsson A, Felch N, Luttgen M, Kolatkar A, Hicks JB, Kuhn P.  Sequential monitoring of androgen receptor expression and copy number variation in castration-resistant prostate cancer. ASCO 2013 Annual Meeting, poster presentation (abstr 11047).

 

Liu SV, Dempsey PW, Strauss W, Xu Y, Xu T, Pinski JK, Dorff TB, Quinn DI, Triche TJ, Winer-Jones J, De Fusco A, McMurdie J, Goldkorn A;. Targeted next-generation sequencing of circulating tumor cells in hormone-sensitive prostate cancer. ASCO 2013 Annual Meeting, poster presentation (abstr 11040). 

 

Quinn DI, Groshen S, Shah M, Tsao-Wei D, Garcia A, Pham H, Lin Y, Ketchens C, Massopust K, Wei M, Longo V, Dorff TB. Final results of a phase I trial of fasting prior to platinum-based chemotherapy. ASCO 2013 Annual Meeting (poster)  abstr 9632.

 

Feldman DR, Hu J, Dorff TB, Patil S, Van Alstine LJ, Momen L, Carousso M, Hughes A, Snively-Solomon J, Ketchens C, Sheinfeld J, Bains MS, Bajorin DF, Bosl GJ, Motzer RJ, Quinn DI. Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). ASCO 2013 Annual Meeting, oral presentation (abstr 4501).

 

Hepgur M, Dorff TB, Brining L, Cai J, Pinski J, Reed M, Luther M, Chan B, Quinn DI.  Identification of inflammatory and biologic markers for predicting clinical response to sipuleucel-T in CRPC. ASCO 2014 Genitourinary cancer symposium (poster) abstr 134.

 

Hepgur M, Dorff TB, Brining L, Cai J, Pinski J, Reed M, Luther M, Chan B, Quinn DI. Clinical and biologic factors for immune response to sipuleucel-T for metastatic castrate resistant prostate cancer. ASCO 2014 Genitourinary Cancer Symposium (poster) abstr 219.

 

Rini BI,. Dorff TB, Elson P, Suarez C, Humbert J, Pyle L, Larkin JMG, Plimack ER. A prospective observational study of metastatic renal cell carcinoma prior to initiation of systemic therapy. ASCO 2014 Annual Meeting, poster highlights session (abstr 4520).

 

Dorff TB, Groshen S, Quinn DI, Goldkorn A, Martel C, Pinski JK, Kuhn P, Gross ME. Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naïve metastatic castrate-resistant prostate cancer. ASCO 2014 Annual Meeting (poster)TPS abstr 5108.

 

Beam E, Yang D, Ji L, Quinn D, Groshen S, Pinski J, Dorff T. Quality of life in patients receiving herbal therapy for biochemically recurrent prostate cancer. PCF Scientific Retreat 2014 in Carlsbad (poster).

 

Hepgur MF, Dorff TB, Cai J, Reed M, Chan B, Quinn DI. Dynamic changes in biomarkers for immune response to sipuleucel-T for metastatic castrate-resistant prostate cancer. ASCO Genitourinary Cancer Symposium 2015, poster presentation (abstr 181). 

 

Nussbaum N, Dorff TB, Abernethy A, Dolan C, Flanders S, Oestreicher N, George DJ. Health-related quality of life in metastatic castration-resistant prostate cancer: a critical literature review. Value in Health 2015; 18 (abstr PCN126).

 

Quinn DI, Ruel N, Twardowski P, Groshen SG, Dorff TB, Pal SK, Stadler WM, Aparicio A, Lara P, Newman EM.  Eribulin in advanced urothelial cancer patients: a california cancer consortium clinical trial-NCI/CTEP 7435. ASCO Annual Meeting 2015 in Chicago, oral presentation (abstr 4504).

 

Gross ME, Dorff TB, Quinn DI, Massopust K, Diaz PM, Castellanos OO, Agus DB. Safety and efficacy of everolimus, bevacizumab, and docetaxel for castration resistant prostate cancer. ASCO Annual Meeting 2015 in Chicago, poster presentation (abstr 5066).

 

Dorff TB, Longmate J, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao AR, Hu J, Quinn DI, Lara P. Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer: a California cancer consortium clinical trial. ASCO Annual Meeting 2015 in Chicago, poster presentation (abstract 4542). 

 

Tran A, Loh J, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB.  Baseline glomerular filtration rate and cisplatin-induced renal toxicity in urothelial cancer patients. ASCO GU Cancer Symposium 2016 in San Francisco, poster presentation (abstr 380).

 

Dorff TB, Longmate J, Groshen S, Stadler WM, Fishman M, Vaishampayan U, Pal SK, Pinski J, Hu J, Quinn DI, Lara PN.  Serum and tissue biomarkers of bevacizumab-based treatment in metastatic renal cell carcinoma (RCC): a California Cancer Consortium trial. ASCO GU Cancer Symposium 2016 in San Francisco, poster presentation (abstr 522).

Page 1 of 15